PDS Biotechnology Corporation (PDSB) NASDAQ
1.14
+0.06(+5.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.14
+0.06(+5.56%)
Currency In USD
| Previous Close | 1.08 |
| Open | 1.07 |
| Day High | 1.22 |
| Day Low | 1.06 |
| 52-Week High | 1.92 |
| 52-Week Low | 0.51 |
| Volume | 1.35M |
| Average Volume | 926,623 |
| Market Cap | 63.63M |
| PE | -1.73 |
| EPS | -0.66 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 0.94 |
| Change | 0.06 |
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
GlobeNewswire Inc.
Feb 20, 2026 1:30 PM GMT
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck CancerPRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage i
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
GlobeNewswire Inc.
Jan 28, 2026 1:45 PM GMT
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Compa
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
GlobeNewswire Inc.
Jan 22, 2026 1:45 PM GMT
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 YearsPRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the